ScreenerHero

TKNOAlpha Teknova Inc. Common Stock

NAS · US · Healthcare · Drug Manufacturers - Specialty & Generic · teknova.com
7.360USD+2.08%Mkt Cap: 395.15M $P/E: —

Alpha Teknova, Inc. produces critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics in the United States and internationally. The company' primary …

Industry Peers

Drug Manufacturers - Specialty & Generic
Screen all
MRK
MERCK Kommanditgesellschaft auf Aktien
$65.19BUSDP/E 23.7
TAK
Takeda Pharmaceutical Co. Ltd.
$58.06BUSD
HLN
Haleon plc American Depositary Shares (Each representing two Ordinary Shares)
$43.98BUSDP/E 20.4
TEVA
Teva Pharmaceutical Industries Limited
$43.51BUSDP/E 62.2
ZOE
Zoetis Inc.
$29.89BUSDP/E 12.7
ZTS
Zoetis Inc.
$32.12BUSDP/E 12.7
UTHR
United Therapeutics Corporation
$22.01BUSDP/E 18.4
VTRS
Viatris, Inc.
$18.75BUSD
SOBI
Swedish Orphan Biovitrum AB
$15.34BUSDP/E 117.3
IPN
Ipsen S.A.
$14.67BUSDP/E 26.4
NBIX
Neurocrine Biosciences, Inc.
$15.51BUSDP/E 22.3
ELAN
Elanco Animal Health Incorporat
$11.98BUSD
RDY
Dr. Reddy's Laboratories Ltd
$10.15BUSDP/E 29.7
KRK
Krka, d. d.
$8.66BUSDP/E 19.0
ALKS
Alkermes plc
$8.11BUSDP/E 127.2
HIMS
Hims & Hers Health, Inc.
$7.88BUSD
LNTH
Lantheus Holdings Inc
$6.53BUSDP/E 23.9
AMRX
Amneal Pharmaceuticals, Inc. Class A
$6.24BUSDP/E 37.3
LQDA
Liquidia Corporation
$6.14BUSDP/E 49.0
KNSA
Kiniksa Pharmaceuticals, Ltd.
$6.08BUSDP/E 79.8

Key Statistics

Company
Market Cap395.15M $
Enterprise Value385.79M $
Revenue (TTM)43.70M $
Gross Profit13.44M $
Net Income (TTM)-17.26M $
Revenue/Share0.8160 USD
Last Price7.360 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees158
CountryUS
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-36.84
PEG—
EV/EBITDA-42.99
EV/Revenue8.83
P/S8.60
P/B6.00
EPS (TTM)-0.31
EPS (Forward)-0.19
52W Range
1.91092% of range7.840
52W High7.840 USD
52W Low1.910 USD
Profitability
Gross Margin33.17%
Oper. Margin-23.72%
EBITDA Margin-20.53%
Profit Margin-42.59%
ROE-25.09%
ROA-16.66%
Growth
Revenue Growth18.50%
Earnings Growth—
Cash Flow & Leverage
Operating CF-8.65M $
CapEx (TTM)1.15M $
FCF Margin-1.68%
FCF Yield-0.19%
Net Debt9.97M $
Net Debt/EBITDA-1.11
Balance Sheet
Debt/Equity0.41
Current Ratio4.49
Quick Ratio3.32
Book Value/Sh1.166 USD
Cash/Share0.3250 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.3 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)8.600 USD
Upside (mean)+16.8%
Target Range7.000 USD – 12.00 USD
$7.000+16.8% to mean$12.00
# Analysts5
Ownership
Shares Out.53.69M
Float10.99M
Insiders9.31%
Institutions87.31%
Short Interest
Short Ratio12.3d
Short % Float13.59%
Short % Out.2.78%
Shares Short1.49M
Short (prev mo.)1.25M
Technical
SMA 505.594 (+31.6%)
SMA 2004.071 (+80.8%)
Beta0.68
S&P 52W Chg18.16%
Avg Vol (30d)202.56K
Avg Vol (10d)398.08K
Technical Indicators
RSI (14)76.5
MACD0.5848
MACD Signal0.4623
MACD Hist.+0.1225
BB Upper8.153 USD
BB Middle6.107 USD
BB Lower4.062 USD
BB Width66.98%
ATR (14)0.5331 USD
Vol Ratio (20d)0.93x